Neusoft Medical Systems Co., Ltd, a leading Chinese medical technology company, has announced a strategic agreement with the Center for Information of the National Medical Products Administration (NMPA) of China. The collaboration aims to conduct in-depth research, innovative application, and practice exploration of artificial intelligence (AI) in the realm of drug intelligent administration. The joint efforts will be centered around the “AI+drug intelligent administration” R&D application platform.
Leveraging Neusoft’s Technological Expertise in AI and Big Data
This partnership will capitalize on Neusoft’s strengths in technology, talent, and innovation, particularly in the fields of AI and big data. The company will collaborate with the NMPA to study and construct a vertical large-scale model for drug regulation. This model will be the focus of in-depth training and development efforts.
Enhancing Drug Regulation with Data Analysis and AI
The collaboration’s primary goal is to unlock the full potential of drug regulation data through deep mining and extensive data analysis. By doing so, the intelligence level and regulatory efficiency of drug regulation are expected to be significantly enhanced. This initiative will provide a scientific basis for decision-making, benefiting both government entities and enterprises in the pharmaceutical sector.-Fineline Info & Tech
